Chiusura precedente | 92,77 |
Aperto | 92,39 |
Denaro | 0,00 x 0 |
Domanda | 0,00 x 0 |
Min-Max giorno | 91,25 - 92,57 |
Intervallo di 52 settimane | 79,21 - 94,52 |
Volume | |
Media Volume | 3.297.214 |
Capitalizzazione | 187,187B |
Beta (mensile su 5 anni) | 0,47 |
Rapporto PE (ttm) | 22,76 |
EPS (ttm) | 4,03 |
Prossima data utili | 18 lug 2024 |
Rendimento e dividendo (futuro) | 3,30 (3,60%) |
Data ex dividendo | 07 mar 2024 |
Stima target 1A | 86,92 |
Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali® (ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer recurrence across a broa
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and commence trading today on the SIX Swiss ExchangeSpin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicinesNovartis pipeline one of the industry’s most competitive, focused on key next-generation platforms and four core therapeutic areasCo
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide5–9 Novar